Skip to main content
Close

Glomerulonephritis

About

Glomerulonephritis (GN) is a group of kidney diseases which while relatively rare, represent the second most common cause of end-stage renal disease in Canada. GN appears to be increasing in prevalence and disproportionately affecting younger Canadians. Along with our GN Network and Registry and international collaborators, our research aims to identify risks and address gaps and barriers to best care for GN patients. 

Publications and Presentations

Publications


  • Barbour S, Feehally J. (2017). An update on the treatment of IgA nephropathy. Current Opinion in Nephrology and Hypertension. 26(4):319-326.
  • Hutton HL, Levin A, Gill J, Djurdjev O, Tang M, Barbour SJ. (2017). Cardiovascular risk is similar in patients with glomerulonephritis compared to other types of chronic kidney disease: a matched cohort study. Bmc Nephrology.18:10.
  • Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC, Derivation O, Valiga Consortia. (2016). The MEST score provides earlier risk prediction in lgA nephropathy. Kidney international.89(1):167-75.
  • Gu B, Magil AB, Barbour SJ. (2016). Frequently relapsing anti-glomerular basement membrane antibody disease with changing clinical and phenotype and antibody characteristics over time. Clinical kidney journal.9(5):661-664.
  • Mann S, Seidman MA, Barbour SJ, Levin A, Carruthers M, Chen LY. (2016). Recognizing IgG4-related tubulointerstitial nephritis. Canadian journal of kidney health and disease.3:34.
 
  • Barbour S, Gill JS. (2015). Advances in the understanding of complement mediated glomerular disease: implications for recurrence in the transplant setting. American journal of transplantation. 15(2): 312-9 
  • Barbour, SJ, Cattran, DC, Espino-Hernandez, G, Hladunewich, MA, Reich, HN. (2015). Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis. Kidney Int, 88(6), 1392-1401.
  • Fervenza, FC, Canetta, PA, Barbour, SJ, Lafayette, RA, Rovin, BH, Aslam, N, Hladunewich, MA, Irazabal, MV, Sethi, S, Gipson, DS, Reich, HN, Brenchley, P, Kretzler, M, Radhakrishnan, J, Hebert, LA, Gipson, PE, Thomas, LF, McCarthy, ET, Appel, GB, Jefferson, JA, Eirin, A, Lieske, JC, Hogan, MC, Greene, EL, Dillon, JJ, Leung, N, Sedor, JR, Rizk, DV, Blumenthal, SS, Lasic, LB, Juncos, LA, Green, DF, Simon, J, Sussman, AN, Philibert, D, Cattran, DC, Global Mentor Consortium. (2015). A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)', Nephron, (1303), 159-168.
  • Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, Cerda J. (2015). Randomized Controlled Trial of Mycophenolate Mofetil in Children, Adolescents, and Adults With IgA Nephropathy. American Journal of Kidney Diseases. 66(5):783-91.
 
  • Barbour, S, Beaulieu, M, Gill, J, Espino-Hernandez, G, Reich, HN, Levin, A. (2014). The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists. Clin Kidney J, 7(6), 538-45.
  • Lee, T, Biddle, AK, Lionaki, S, Derebail, VK, Barbour, SJ, Tannous, S, Hladunewich, MA, Hu, YC, Poulton, CJ, Mahoney, SL, Jennette, JC, Hogan, SL, Falk, RJ, Cattran, DC, Reich, HN, Nachman, PH. (2014). Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney International, 85(6), 1412-1420.
  • Barbour S, Beaulieu M, Gill J, Djurdjev O, Reich H, Levin A. An overview of the British Columbia Glomerulonephritis network and registry: integrating knowledge generation and translation within a single framework. BMC nephrology. 14(1).
  • Barbour S, Reich H, Cattran D. Short-term complications of membranous nephropathy. Contributions to Nephrology. 181.
  • Barbour SJ, Cattran DC, Kim SJ, Levin A, Wald R, Hladunewich MA, Reich HN. (2013). Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney international. 84(5):1017-24.
 
  • Barbour S, Greenwald A, Djurdjev O, Levin A, et al. Disease-specific risk venous thromboembolic events in idiopathic glomerulonephritis. KI, Jan 2012; 81(2):190-5.
  • Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. American Journal of Kidney Diseases. 59(6).
  • Lionaki S, Derebail VK, Hogan SL, Barbour S, et al. Venous thromboembolism in patients with membranous nephropathy. Clinical Journal of the American Society of Nephrology. 7(1).
  • Lv J, Perkovic V, Ma X, Johnson D, Woodward M, Levin A, Zhang H, Wang H. Corticosteroid Therapy in IgA Nephropathy. JASN. Apr 2012; 23:1108-16. 
 

  • Barbour SJ, Beaulieu MC, Zalunardo NY, Magil AB. (2011). Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases. Nephrol Dial Transplant. 26(8):2712-4.   

  • Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010 Jan;55(1):50-60.
  • Schachter ME, Monahan M, Radakrishnan J, Crew J, Pollak M, Ratner L, Valeri AM, Stokes BM, Appel GB. (2010). Recurrent focal segmental glomerulosclerosis in the renal allograft: Single center experience in the era of modern immunosuppression. Clinical Nephrology. [Epub ahead of print]. 

Presentations

 
 
 

Tab Heading
Tab Heading
SOURCE: Glomerulonephritis ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Renal Agency. All Rights Reserved.

    Copyright © 2017 Provincial Health Services Authority